antivir
therapi
crucial
circumvent
viral
epidem
unavail
specif
antivir
drug
chikungunya
viru
chikv
diseas
creat
alarm
situat
identifi
develop
potent
chemic
molecul
remedi
manag
chikv
present
investig
silico
studi
dihydrorugosaflavonoid
deriv
nonstructur
carri
replic
protein
recent
consid
possibl
antivir
target
crucial
inhibitor
fit
adenosinebind
pocket
macrodomain
dihydrorugosaflavonoid
display
intrins
bind
macrodomain
pdb
id
chikv
compound
show
dock
score
kcal
mol
respect
variou
vitro
assay
perform
confirm
antivir
potenti
chikv
noncytotox
dose
determin
bromid
assay
found
compound
show
inhibitori
potenti
chikv
determin
cytopath
effect
assay
plaqu
reduct
assay
show
inhibit
concentr
compound
respect
quantit
realtim
polymeras
chain
reaction
assay
result
confirm
abil
reduc
viral
rna
level
concentr
compound
nearli
concentr
respect
cell
chikv
infect
chikvinhibitori
capac
compound
corrobor
execut
immunofluoresc
assay
execut
work
meaning
futur
research
studi
dihydrorugosaflavonoid
prime
antivir
entrant
lead
remedi
manag
preclud
chikv
infect
case
chikungunya
viral
fever
burgeon
everi
year
infect
limit
asia
africa
recent
epidem
chikungunya
report
central
south
america
concern
data
obtain
nation
vector
born
diseas
control
programm
nvbdcp
india
number
infect
peopl
identifi
april
karnataka
follow
gujarat
maharashtra
earlier
research
studi
shown
consider
resourc
burden
chikungunya
outbreak
escal
monsoon
postmonsoon
season
therefor
case
chikungunya
viral
fever
increas
contin
asia
variou
part
world
name
chikungunya
origin
makond
mean
becom
twist
denot
curv
appear
go
joint
ach
result
chikungunya
infect
chikungunya
viru
chikv
spread
mosquito
vector
aed
aegypti
aed
albopictu
common
eukaryot
host
primat
human
human
symptom
associ
chikv
nausea
fever
joint
pain
vomit
rash
persist
arthralgia
clinic
manifest
one
base
diagnosi
chikungunya
infect
confirm
diseas
made
laboratori
test
suspect
case
valid
posit
antichikungunya
viru
igm
igg
result
posit
polymeras
chain
reaction
pcr
result
togavirida
famili
chikv
come
genu
alphaviru
alphavirus
configur
envelop
positivesens
singlestrand
rna
virus
member
alphaviru
genu
member
genu
contain
sever
anim
human
virus
like
ross
river
viru
sindbi
viru
sinv
western
equin
enceph
viru
weev
semiliki
forest
viru
sfv
venezuelan
equin
enceph
viru
veev
etc
furthermor
categor
old
world
new
world
virus
reliant
chang
occur
life
cycl
fatal
clinic
manifest
basic
old
world
virus
chikv
sinv
sfv
etc
engag
protein
downregul
host
cell
transcript
less
demis
percentag
stimul
arthralgia
new
world
virus
veev
weev
etc
use
viru
capsid
protein
cp
downregul
host
cell
transcript
high
casualti
frequenc
gener
enceph
crystallograph
studi
cryoelectron
microscopi
differ
alphavirus
protein
deliv
vital
inform
regard
molecular
organ
distribut
virion
structur
portion
encapsid
copi
cp
rna
genom
chikv
make
nucleocapsid
core
grownup
alphaviru
virion
nm
diamet
envelop
deriv
host
icosahedr
symmetri
embed
spike
trimer
surfac
glycoprotein
heterodim
build
everi
spike
chikv
bear
genom
almost
kb
polyadenyl
end
cap
end
nonstructur
polyprotein
encod
twothird
open
read
frame
orf
genom
three
chief
structur
protein
capsid
c
encod
onethird
orf
genom
function
nonstructur
protein
nsp
promot
construct
distinct
matur
nonstructur
protein
cap
enzym
viral
helicas
proteas
rnadepend
rna
polymeras
intrins
disord
ntermin
domain
role
well
defin
howev
recent
mcpherson
et
al
report
chikv
macrodomain
hydrolyz
adpribos
group
mono
adpribosyl
ate
protein
activ
mono
adpribosyl
hydrolas
somewher
decis
chikv
replic
virul
mice
nterminu
encompass
preserv
macrodtyp
macrodomain
protein
fold
macrodomain
remark
conserv
present
numer
plusstrand
rna
virus
attach
adpribos
mutant
virus
miss
hydrolas
activ
incap
replic
mammalian
cell
mosquito
albopictu
cell
quickli
regress
catalyt
inactiv
mutant
despit
increas
number
chikungunya
patient
haplessli
date
antivir
remedi
vaccin
avail
market
cure
chikvinfect
patient
chikv
vaccin
approach
analyz
togeth
ineffici
live
weaken
dna
chimer
vaccin
howev
question
associ
protect
effici
stall
develop
current
vaccin
entrant
besid
drug
testifi
via
vitro
screen
chloroquin
ribavirin
arbidol
curb
chikv
progress
fail
produc
noteworthi
therapeut
aid
clinic
sampl
recent
past
highthroughput
assay
establish
figur
probabl
inhibitor
chikv
literatur
search
provid
inform
regard
analysi
natur
product
molecul
clinic
recommend
medicin
counteract
chikv
replicon
accompani
test
surrog
infect
model
semliki
forest
viru
sfv
analys
small
compound
inhibitor
chikv
also
test
phenotyp
assay
protocol
still
problem
prevent
treatment
chikv
fever
recalcitr
therefor
necessari
work
streamlin
manner
overcom
sever
menac
flavon
natur
occur
polyphenol
secondari
metabolit
exist
plant
shown
enorm
potenti
field
medicin
chemistri
benefici
daili
life
boost
immun
use
prevent
measur
variou
ailment
consum
flavonerich
product
green
tea
fruit
etc
laboratori
prepar
natur
occur
rugosaflavonoid
deriv
format
rugosaflavonoid
obtain
dihydrorugosaflavonoid
scheme
screen
compound
tuberculosi
previou
studi
found
halogen
dihydrorugosaflavonoid
much
better
antitubercular
agent
rugosaflavonoid
due
nonavail
antivir
drug
chikv
mostli
natur
compound
subject
screen
antivir
activ
obtain
lead
molecul
use
highthroughput
assay
therefor
studi
check
antivir
potenti
compound
chikv
first
use
molecular
dock
target
site
compound
identifi
chikv
nonstructur
viral
protein
crucial
role
replic
surviv
chikv
among
natur
ligand
adpribos
bind
macrodomain
highli
conserv
dock
compound
macrodomain
indic
halogen
dihydrorugosa
articl
flavonoid
interact
fit
effect
pocket
bind
properti
halogen
dihydrorugosaflavonoid
invigor
us
screen
compound
antivir
efficaci
chikv
studi
dock
potenti
dihydrorugosaflavonoid
deriv
macrodomain
antivir
potenti
chikv
report
base
outcom
antivir
screen
use
chikvinfect
vero
cell
dihydrorugosaflavonoid
assess
sever
assay
cytopath
effect
cpe
inhibit
plaqu
reduct
assay
conduct
determin
inhibitori
potenti
compound
chikv
replic
quantit
realtim
polymeras
chain
reaction
qrtpcr
perform
assess
reduct
viral
rna
level
infect
cell
immunofluoresc
assay
ifa
carri
investig
reduct
chikv
antigen
upon
treatment
screen
compound
chemistri
dihydrorugosaflavonoid
moieti
three
ring
b
c
figur
synthes
compound
dissimilar
ring
b
ring
hydroxyl
group
th
posit
ester
group
posit
rest
chang
ring
b
differ
substitut
benzen
obtain
synthesi
analogu
rugosaflavonoid
intermedi
synthesi
final
product
scheme
per
gaspar
et
al
flavonoid
still
valid
scaffold
medicin
chemistri
recent
lani
et
al
publish
antivir
potenti
baicalein
fisetin
chikv
compound
possess
backbon
pertin
check
inhibitori
potenti
chikv
recent
synthesi
compound
report
group
spectral
data
provid
support
inform
support
inform
file
silico
studi
molecular
dock
halogen
dihydrorugosaflavonoid
three
key
domain
central
zincbind
region
conserv
ntermin
macrodomain
poorli
conserv
properli
structur
acid
highli
phosphoryl
ctermin
domain
function
variou
cellular
protein
influenc
signal
stress
granul
assembl
viral
replic
control
ctermin
domain
exact
role
central
zincbind
region
ntermin
macrodomain
well
categor
macrodomain
known
conserv
protein
fold
detect
archaea
higher
eukaryot
consid
affin
small
molecul
adpribos
analogu
positivestrand
rna
virus
alphavirus
coronavirus
hepat
e
viru
macrodomain
integr
part
nsp
accord
rungrotmongkol
et
al
molecular
understand
particular
bind
adpribos
chikv
macrodomain
reveal
amino
acid
asp
ile
asn
asp
gli
val
cy
ser
val
arg
act
critic
residu
bind
pocket
make
molecular
contact
ligand
also
ribos
diphosph
unit
adpribos
found
play
signific
role
make
molecular
contact
amino
acid
residu
chikv
adpribos
complex
figur
b
chloro
deriv
dihydrorugosaflavonoid
show
interact
halogen
arg
figur
carbonyl
oxygen
ring
c
form
hydrogen
bond
ser
thr
gli
asp
ile
also
nearbi
val
interact
ring
oxygen
also
show
bond
leu
thr
interact
carboxyl
group
attach
ring
amino
acid
residu
bind
pocket
critic
also
activ
bind
macrodomain
adpribos
tabl
bromo
deriv
rugosaflavonoid
show
bind
potenti
site
pocket
macrodomain
show
interact
asn
gli
asp
figur
dock
score
found
kcal
mol
respect
tabl
effect
bind
interact
tabl
indic
compound
may
interfer
function
macrodomain
thu
inhibit
replic
chikv
therefor
evalu
inhibitori
potenti
halogen
dihydrorugosaflavonoid
chikv
antivir
assay
perform
use
vero
cell
line
observ
cytopath
effect
cpe
plaqu
reduct
assay
quantif
viral
genom
rna
qrtpcr
use
immunofluoresc
imag
admet
analysi
process
drug
discoveri
develop
variou
rule
consid
suffer
variou
limit
therefor
combin
pharmacodynam
pd
pharmacokinet
pk
explain
interact
organ
drug
import
studi
pd
evalu
drug
bodi
pk
explain
bodi
respond
drug
main
compon
pk
absorpt
distribut
metabol
excret
adm
final
associ
toxic
admet
although
adm
properti
explain
utmost
pharmacolog
perform
small
molecul
toxicolog
studi
ensur
injuri
organ
side
effect
accord
hodgson
chemic
drug
matter
activ
specif
action
unless
also
taken
appropri
bodi
absorpt
distribut
right
part
bodi
metabol
way
instantli
remov
activ
elimin
suitabl
drug
must
get
move
hang
around
get
haplessli
address
paramet
timeconsum
cumbersom
due
intricaci
human
bodi
paramet
affect
limit
interact
within
bodi
also
sever
restrict
due
gender
age
genet
state
diseas
etc
case
silico
technolog
help
comput
calcul
base
mathemat
algorithm
use
silico
softwar
although
give
full
guaranti
go
work
live
system
save
time
select
molecul
consid
studi
therefor
admet
properti
studi
use
qikprop
softwar
maestro
tabl
valu
paramet
qp
log
pow
qp
log
herg
qpp
caco
qp
log
bb
qpp
mdck
qp
log
kp
qp
log
k
hsa
percentag
human
oral
absorpt
shown
compound
qp
log
pow
report
expect
octanolwat
partit
coeffici
rang
valu
obtain
qp
log
herg
predict
ic
valu
blockag
herg
k
channel
defin
rang
give
idea
appar
cell
permeabl
nm
cell
model
barrier
consid
poor
consid
significantli
good
comput
valu
compound
found
great
poor
also
qp
log
bb
calcul
partit
coeffici
accept
rang
compound
studi
show
valu
qpp
mdck
predict
appar
mdck
cell
permeabl
nm
mdck
cell
identifi
good
imit
barrier
accept
rang
valu
dihydrorugosaflavonoid
obtain
qp
log
kp
predict
skin
permeabl
accept
rang
compound
valu
obtain
qp
log
k
hsa
predict
affin
toward
human
serum
albumin
toler
limit
compound
valu
rang
mention
percentag
human
oral
absorpt
rang
weak
signific
compound
valu
obtain
result
support
compound
valu
accept
rang
antivir
studi
cell
cytotox
test
tetrazoliumbas
cell
viabil
assay
conduct
investig
detect
maximum
nontox
dose
mntd
compound
bromid
mtt
assay
depend
reaction
watersolubl
compound
mtt
insolubl
formazan
product
viabl
cell
activ
metabol
activ
thu
color
produc
due
format
formazan
suitabl
marker
viabl
cell
differ
concentr
compound
assess
mtt
assay
h
compound
display
toxic
vero
cell
viabl
figur
b
halfmaxim
cytotox
cc
calcul
plot
graph
repres
dot
line
antivir
assay
perform
use
concentr
compound
assess
antivir
activ
via
cytopath
effect
evalu
mntd
compound
differ
noncytotox
concentr
compound
screen
virusinfect
vero
cell
find
possibl
effect
compound
viralinduc
cytopath
effect
cpe
assay
evalu
hpi
support
inform
file
compound
exhibit
signific
reduct
chikvinduc
cpe
less
concentr
plaqu
reduct
assay
reduct
chikv
infect
presenc
compound
assess
plaqu
reduct
assay
case
chikv
viru
inhibit
observ
dihydrorugosaflavonoid
qp
log
pow
predict
octanolwat
partit
coeffici
accept
rang
qp
log
herg
predict
ic
valu
blockag
herg
k
channel
accept
rang
qpp
caco
predict
appar
cell
permeabl
nm
cell
model
barrier
nm
poor
great
qp
log
bb
predict
brainblood
partit
coeffici
qpp
mdck
predict
appar
mdck
cell
permeabl
nm
poor
great
mdck
cell
consid
good
mimic
barrier
qp
log
kp
predict
skin
permeabl
qp
log
k
hsa
predict
bind
human
serum
albumin
accept
rang
percentag
human
oral
absorpt
poor
high
nearli
concentr
show
compar
control
figur
compound
show
inhibit
chikv
effect
concentr
ec
determin
antivir
curv
ec
compound
figur
select
index
cc
ec
cc
figur
ec
compound
figur
select
index
cc
figur
report
ec
valu
mean
two
experi
perform
triplic
clearli
show
dihydrorugosaflavonoid
possess
better
inhibitori
potenti
substitut
dihydrorugosaflavonoid
compound
chikv
quantit
realtim
pcr
convent
rtpcr
method
still
one
reliabl
diagnost
method
studi
viral
load
supernat
clinic
sampl
qrtpcr
use
valid
antivir
effect
quantifi
chikv
rna
level
infect
cell
reduct
viral
rna
level
observ
treat
compound
hpi
chikv
rna
level
upon
treatment
reduc
close
respect
wherea
case
rna
level
chikv
reduc
respect
figur
immunofluoresc
assay
ifa
immunofluoresc
stain
allow
rapid
diagnosi
viral
antigen
infect
cell
use
monoclon
antibodi
virusspecif
antigen
one
two
envelop
glycoprotein
present
chikungunya
viru
name
glycoprotein
use
viral
antigen
studi
viru
detect
ifa
chikv
moi
propag
vero
cell
h
compound
concentr
ifa
measur
detect
intracellular
viru
envelopespecif
monoclon
antibodi
mab
addit
visual
neg
control
sampl
chikvinfect
cell
posit
figur
clearli
show
compound
inhibit
chikv
concentr
due
nonavail
antivir
drug
vaccin
chikv
variou
approach
consid
world
identifi
lead
molecul
restrict
chikv
infect
replic
piec
work
molecular
dock
dihydrorugosaflavonoid
show
interact
key
residu
bind
adp
support
possibl
indic
compound
potenti
antivir
chikv
confirm
studi
perform
variou
antivir
assay
cpe
plaqu
reduct
assay
display
compound
potenti
inhibit
chikv
infect
qrtpcr
assay
result
clearli
show
potenti
two
compound
suppress
viral
rna
level
infect
cell
furthermor
antivir
activ
dihydrorugosaflavonoid
toward
chikv
also
well
deliv
ifa
flavonoid
compound
receiv
mani
reward
show
potenti
medicin
chemistri
dihydrorugosaflavonoid
belong
class
display
potenti
inhibit
chikv
replic
conclus
could
explic
halogen
dihydrorugosaflavonoid
appropri
modif
deserv
candid
addit
studi
find
accur
fact
mechan
action
effect
antichikv
therapeut
gener
remark
chemic
util
reaction
obtain
spectrochem
india
h
nmr
c
nmr
spectra
record
room
temperatur
varian
mhz
mhz
spectromet
respect
chemic
shift
valu
display
refer
tm
intern
standard
dmsod
use
solvent
prepar
sampl
chemic
shift
express
ppm
coupl
constant
j
hertz
split
pattern
abbrevi
follow
singlet
doublet
triplet
q
quartet
unresolv
multiplet
dd
doublet
doublet
column
chromatographi
perform
merck
silica
gel
mesh
analyt
thinlay
chromatographi
carri
use
merck
silica
gel
iodin
use
develop
reagent
ir
spectra
record
ftir
ir
shimadzu
spectrophotomet
chn
analysi
record
elementar
vario
eliii
molecular
dock
protein
prepar
protein
pdb
code
prepar
perform
use
maestro
softwar
protocol
earlier
publish
paper
protein
taken
rcsb
site
wwwrcsborg
ligand
prepar
dihydrorugosaflavonoid
deriv
design
ligand
ligand
suitabl
prepar
use
ligprep
tool
softwar
protocol
follow
per
report
procedur
receptor
grid
gener
glide
tool
use
gener
receptor
grid
protocol
follow
per
procedur
report
puranik
et
al
glide
molecular
dock
molecular
dock
dihydrorugosaflavonoid
establish
help
glide
tool
comput
studi
carri
per
protocol
report
adm
properti
calcul
adm
properti
ligand
molecul
obtain
qikprop
tool
schroding
deliv
inform
absorpt
distribut
metabol
excret
toxic
admet
properti
ligand
provid
data
qp
log
pow
qp
log
bb
overal
cn
activ
mdck
cell
permeabl
log
k
hsa
human
serum
albumin
bind
percentag
human
oral
absorpt
etc
method
conduct
per
protocol
publish
chemistri
compound
intermedi
synthes
per
procedur
report
previou
publish
paper
detail
provid
support
inform
file
antivir
cellbas
assay
cell
virus
vero
cell
ncc
pune
india
maintain
dulbecco
modifi
eagl
medium
dmem
himedia
india
supplement
heatinactiv
fetal
bovin
serum
fb
gibco
unit
penicillin
mg
streptomycinml
co
incub
use
viru
adsorpt
techniqu
chikv
access
number
strain
stock
prepar
vero
cell
store
need
use
plaqueform
assay
viru
titer
calcul
plaqueform
unit
per
millilit
pfuml
use
quantifi
viru
titer
cytotox
studi
cytotox
compound
vero
cell
measur
use
mtt
sigma
plate
format
stock
compound
prepar
dissolv
dimethyl
sulfoxid
dmso
work
concentr
prepar
dilut
cultur
media
confluenc
media
remov
media
contain
differ
dilut
compound
ad
well
well
dmso
consid
control
h
mtt
ad
volum
mg
ml
stock
incub
h
co
upon
complet
incub
dmso
ad
dissolv
formazan
crystal
absorb
read
wavelength
nm
use
citat
three
multimod
plate
reader
biotek
instrument
inc
experi
done
triplic
assess
antivir
activ
vero
cell
seed
onto
plate
cell
densiti
cellswel
cell
treat
compound
h
prior
infect
infect
moi
cell
monolay
infect
chikv
gentl
shake
everi
min
min
inoculum
discard
cell
monolay
wash
twice
ensur
chanc
secondari
infect
compound
also
ad
postinfect
media
contain
dmem
fb
h
infect
infect
cell
incub
dmso
neg
control
hpi
supernat
collect
determin
viru
titer
plaqueform
assay
collect
supernat
trizol
thermo
fisher
scientif
ad
per
manufactur
protocol
adher
cell
plate
isol
rna
qrtpcr
furthermor
cpe
chikv
vero
cell
line
appear
h
cell
infect
henc
effect
inhibitori
compound
cpe
observ
hpi
invert
light
microscop
carl
zeiss
germani
cell
viabil
antivir
curv
use
determin
ec
cc
ratio
cc
ec
select
index
gave
idea
therapeut
window
dihydrorugosaflavonoid
compound
plaqu
reduct
assay
perform
plaqu
assay
measur
viru
titer
vero
cell
monolay
seed
plate
cell
per
well
compound
treatment
infect
describ
assess
antivir
activ
final
dmso
concentr
compound
vv
infect
cell
treat
vari
concentr
compound
dmem
fb
incub
co
h
hpi
cell
supernat
harvest
serialdilut
chikv
supernat
ad
vero
cell
incub
min
untreat
virusinfect
cell
taken
control
afterward
cell
overlaid
carboxymethyl
cellulos
mem
fb
incub
co
h
overlay
medium
discard
cell
fix
formaldehyd
h
cell
stain
crystal
violet
solut
plaqu
visual
curv
gener
measur
percent
inhibit
plaqu
reduct
assay
particular
rang
compound
concentr
vari
concentr
compound
use
gener
inhibit
curv
calcul
effect
concentr
ec
ec
compound
calcul
plot
graph
percent
inhibit
compound
differ
concentr
vs
compound
concentr
plaqu
reduct
assay
perform
triplic
particular
concentr
compound
repeat
twice
verifi
constant
inhibit
result
quantit
realtim
qrt
pcr
vero
cell
seed
onto
plate
cell
densiti
cell
per
well
compound
treatment
infect
describ
assess
antivir
activ
quantif
viral
genom
h
incub
without
compound
supernat
discard
trizol
ad
plate
rna
purifi
accord
manufactur
protocol
purifi
rna
treat
dnase
remov
trace
genom
dna
promega
subsequ
use
cdna
prepar
use
accuscript
high
fidel
cdna
synthesi
kit
agil
extract
rna
forward
revers
primer
use
amplif
given
tabl
neg
posit
control
includ
pcr
amplif
nucleasefre
water
use
instead
rna
sampl
neg
control
screen
possibl
contamin
rna
extract
untreat
chikv
supernat
use
posit
control
experi
done
triplic
repeat
twice
accuraci
result
pcr
run
carri
accord
standard
kapa
sybr
fast
univers
qpcr
kit
quantstudio
system
appli
biosystem
carlsbad
ca
cycl
condit
follow
cycl
fluoresc
detect
cycl
analyz
data
fold
chang
differ
control
sampl
compoundtr
sampl
calcul
use
valu
immunofluoresc
assay
vero
cell
seed
onto
plate
cell
densiti
cell
per
well
cell
treat
concentr
compound
prior
chikv
infect
hpi
cell
wash
three
time
pb
fix
methanol
aceton
h
room
temperatur
follow
permeabil
wash
cell
incub
antibodi
chikv
ie
antialphaviru
santa
cruz
biotechnolog
inc
h
incub
fluorescein
fitc
conjug
secondari
antimous
antibodi
sigma
min
plate
rins
pb
counterstain
dapi
sigma
min
imag
captur
two
train
person
fluoresc
microscop
leica
microsystem
experi
repeat
thrice
verifi
result
support
inform
avail
free
charg
ac
public
websit
doi
imag
cytopath
effect
spectra
compound
detail
protocol
molecular
model
adm
studi
procedur
synthesi
pdf
